Sulfasalazine is an anti-inflammatory medication used mainly to treat rheumatoid arthritis and inflammatory bowel disease. It acts as a slow-release medication and reduces pain and swelling associated with inflammatory diseases. The product offers relief from joint tenderness, pain, and swelling and helps maintain remission in ulcerative colitis patients. It selectively inhibits proinflammatory cytokines and modulates gut microbiome, thereby exhibiting anti-inflammatory properties.
The global Sulfasalazine Market is estimated to be valued at US$ 2.32 Bn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the sulfasalazine market is the increasing prevalence of rheumatoid arthritis and inflammatory bowel diseases. According to the Arthritis Foundation, around 54 million American adults had arthritis in 2018 and the number is expected to reach 78 million by 2040. Similarly, inflammatory bowel disease prevalence is also on the rise globally. For instance, as per the Crohn’s & Colitis Foundation, around 1.6 million Americans suffer from the inflammatory bowel disease. Sulfasalazine is a first-line drug for treating these autoimmune diseases. Hence, rising incidence of these conditions will drive the demand for sulfasalazine over the forecast period.
Threat of new entrants: The sulfasalazine market has moderate threat of new entrants due to high capital requirements and regulatory barriers. However, increasing investments are lowering these barriers.
Bargaining power of buyers: The bargaining power of buyers is moderate due to availability of substitute drugs however branded drugs have some buyers preference.
Bargaining power of suppliers: The bargaining power of suppliers is high due to limited availability of raw materials and consolidation among API suppliers.
Threat of new substitutes: Threat of substitutes is moderate as there are other competitive anti-inflammatory drugs available in the market.
Competitive rivalry: The market is highly competitive due to presence of global as well as local players.
The Global Sulfasalazine Market Demand is expected to witness high growth over the forecast period.
Regional analysis: North America region currently dominates the sulfasalazine market and is expected to grow at a high rate during the forecast period. The large share is attributed to increasing prevalence of ulcerative colitis and rheumatoid arthritis in the region. Asia Pacific region is anticipated to grow at the fastest rate owing to rising healthcare expenditure and increasing patient pool.
Key players: Key players operating in the sulfasalazine market are Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc. Aptus Biotech S.L. is one of the leading players in the sulfasalazine drug market.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it